BioCentury
ARTICLE | Emerging Company Profile

Pheast: Forty Seven founders reunite for precision macrophage combos

Backed by Catalio and Arch, start-up from Forty Seven founders aims to target patient-specific ‘don’t eat me’ signals beyond CD47

May 10, 2022 12:12 AM UTC

Pheast is developing cancer combination therapies that include a component targeting the latest “don’t eat me” signal: CD24. 

The macrophage checkpoint has overlapping but distinct expression and activation patterns from CD47, the checkpoint Pheast Therapeutics Inc.’s founders pursued at their former company Forty Seven Inc., which means CD24 could find utility in different cancers. ...